sellWeak cluster of 310b5-1 plan
Yale Catriona sold $636k of AKRO
Chief Development Officer at Akero Therapeutics, Inc.. 20,961 shares at an average of $30.37, traded Oct 14, 2024, filed Oct 16, 2024.
Warning score
25Value
$636k
20,961 shares
Holdings after
75,294
-26% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-115138, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | MOption exercise Common Stock10b5-1 | +14,825 | $0.62 | $9,117 | 90,119 | Oct 16, 2024 |
| Oct 15, 2024 | SOpen-market sale Common Stock10b5-1 | -14,525 | $30.50 | $443k | 75,594 | Oct 16, 2024 |
| Oct 15, 2024 | SOpen-market sale Common Stock10b5-1 | -300 | $30.93 | $9,278 | 75,294 | Oct 16, 2024 |
| Oct 14, 2024 | MOption exercise Common Stock10b5-1 | +5,000 | $0.62 | $3,075 | 80,294 | Oct 16, 2024 |
| Oct 14, 2024 | SOpen-market sale Common Stock10b5-1 | -6,136 | $30.03 | $184k | 74,158 | Oct 16, 2024 |
| Oct 15, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,825 | $0.00 | $0 | 13,890 | Oct 16, 2024 |
| Oct 14, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 8,890 | Oct 16, 2024 |
| Oct 15, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 17,959 | Oct 16, 2024 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 51Moderate | buy | AKRO Akero Therapeutics, Inc. | Graham G. Walmsley director | $8.8M | 200,000 | |
| 12Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Yale Catriona Chief Development Officer | $448k | 10,000 | |
| 30Weak | sell 6 | AKRO Akero Therapeutics, Inc. | Rolph Timothy Chief Scientific Officer | $23k | 516 | |
| 42Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | White William Richard Chief Financial Officer | $30k | 676 | |
| 35Weak | sell 6 | AKRO Akero Therapeutics, Inc. | Yale Catriona Chief Development Officer | $28k | 614 | |
| 40Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | Young Jonathan Chief Operating Officer | $27k | 607 | |
| 49Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | Cheng Andrew President and CEO | $78k | 1,738 | |
| 45Moderate | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Cheng Andrew President and CEO | $1.3M | 30,000 | |
| 14Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Rolph Timothy Chief Scientific Officer | $557k | 12,500 | |
| 2Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | Lamy Patrick Senior VP, Commercial Strategy | $48k | 1,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.